How has been the historical performance of Concord Drugs?

Answer:The historical performance of Concord Drugs shows a declining trend in net sales and profits over the past four years.

Breakdown:
Concord Drugs reported net sales of 45.25 Cr in March 2025, a slight increase from 44.93 Cr in March 2024, but a notable decrease from 52.09 Cr in March 2023 and 59.06 Cr in March 2022. Total operating income mirrored this trend, remaining at 45.25 Cr in March 2025, compared to 44.93 Cr in the previous year, but down from 52.09 Cr in March 2023 and 59.06 Cr in March 2022. The total expenditure, excluding depreciation, was 41.11 Cr in March 2025, which was slightly higher than 40.88 Cr in March 2024, but lower than 47.50 Cr in March 2023 and 53.37 Cr in March 2022. Operating profit (PBDIT) was 4.14 Cr in March 2025, showing a marginal increase from 4.05 Cr in March 2024, but down from 4.59 Cr in March 2023 and 5.69 Cr in March 2022. Profit before tax also declined to 0.69 Cr in March 2025 from 0.63 Cr in March 2024, 1.25 Cr in March 2023, and 2.25 Cr in March 2022. The profit after tax followed a similar pattern, decreasing to 0.34 Cr in March 2025 from 0.47 Cr in March 2024, 0.99 Cr in March 2023, and 1.59 Cr in March 2022. The total assets increased to 65.14 Cr in March 2025 from 58.81 Cr in March 2024, while total liabilities also rose to 65.14 Cr from 58.81 Cr in the same period. Cash flow from operating activities was 3.00 Cr in March 2025, up from 0.00 Cr in March 2024, but down from 1.00 Cr in March 2023. Overall, the data indicates a challenging financial environment for Concord Drugs, with declining profitability despite some stability in sales.